A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients

Cancer Prevention Research

Volumn 5, Issue 4, 2012, Pages 621-630

  Messing, Edward ^a   Gee, Jason R ^b,l   Saltzstein, Daniel R ^f   Kim, KyungMann ^b   DiSant'Agnese, Anthony ^b   Kolesar, Jill ^b   Harris, Linda ^b   Faerber, Adrienne ^b,k   Havighurst, Thomas ^b   Young, Jay M ^e   Efros, Mitchell ^g   Getzenberg, Robert H ^h   Wheeler, Marcia A ^j   Tangrea, Joseph ⁱ   Parnes, Howard ⁱ   House, Margaret ⁱ   Busby, J Erik ^c   Hohl, Raymond ^d   Bailey, Howard ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e South Orange County Medical Research Center   (United States)

^f Urology San Antonio Research   (United States)

^g AccuMed Research Associates LLC   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j YALE UNIVERSITY   (United States)

^k UNIVERSITY OF WISCONSIN MADISON   (United States)

^l LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLCA 4 PROTEIN; CASPASE 3; CYCLOOXYGENASE 2; DAIDZEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE B; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ISOFLAVONE DERIVATIVE;

ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; BLADDER CANCER; CALCIUM BLOOD LEVEL; CANCER PREVENTION; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEARTBURN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; BLADDER TUMOR; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SOYBEAN; TIME; URINE;

AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; PLACEBOS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOYBEANS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84864830787     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0455     Document Type: Article

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74.
3. Messing EM. Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th ed. Philadelphia, PA: Saunders Elsevier; 2007.
4. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30. (Pubitemid 38041357)
5. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-97.
6. Borhan A, Reeder JE, O'Connell MJ, Wright KO, Wheeless LL, di Sant'Agnese PA, et al. Grade progression and regression in recurrent urothelial cancer. J Urol 2003;169:2106-9. (Pubitemid 36576727)
7. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530-7. (Pubitemid 20134522)
8. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008;9:55-61.
9. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006;176:500-4. (Pubitemid 43949406)
10. Golijanin DJ, Kakiashvili D, Madeb RR, Messing EM, Lerner SP. Chemoprevention of bladder cancer. World J Urol 2006;24:445-72. (Pubitemid 44793611)
11. Studer UE. [Advanced prostatic carcinoma-which hormone therapy when?]. Urologe A 1995;34:361-6.
12. Peterson G. Evaluation of the biochemical targets of genistein in tumor cells. J Nutr 1995;125 3 Suppl:784S-9S.
13. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833-8. Erratum in: Cancer Res 1999 Mar 15;59(6):1388. (Pubitemid 28405638)
14. Rowell C, Carpenter DM, Lamartiniere CA. Chemoprevention of breast cancer, proteomic discovery of genistein action in the rat mammary gland. J Nutr 2005;135 12 Suppl:2953S-9S. (Pubitemid 43156572)
15. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010;29:465-82.
16. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8:2369-77. (Pubitemid 34753612)
17. Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003;22:4702-9. (Pubitemid 36976445)
18. Chinni SR, Alhasan SA, Multani AS, Pathak S, Sarkar FH. Pleotropic effects of genistein on MCF-7 breast cancer cells. Int J Mol Med 2003;12:29-34.
19. Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC, Song YS. Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann N Y Acad Sci 2009;1171:495-500.
20. Sliva D. Suppression of cancer invasiveness by dietary compounds. Mini Rev Med Chem 2008;8:677-88.
21. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
22. Akiyama T, Ogawara H. Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol 1991;201:362-70.
23. Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31. (Pubitemid 24127628)
24. Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Amer 1992;6:1-30.
25. Su SJ, Yeh TM, Lei HY, Chow NH. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 2000;6:230-6.
26. Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer 1998;78:775-82. (Pubitemid 28530402)
27. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF, Lin JK. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 1999;20:1945-52.
28. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr 2007;137 1 Suppl:205S-10S. (Pubitemid 46052882)
29. Swami S, Krishnan AV, Moreno J, Bhattacharyya RS, Gardner C, Brooks JD, et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer 2009;124:2050-9.
30. Akarasereenont PC, Techatraisak K, Thaworn A, Chotewuttakorn S. The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase. Mediators Inflamm 2002;11:17-22. (Pubitemid 34252543)
31. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8. (Pubitemid 32095036)
32. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-25. (Pubitemid 30482096)
33. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 2003;170:230-4. (Pubitemid 36734468)
34. Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr 2002;76:1126-37. (Pubitemid 35244688)
35. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126-36. (Pubitemid 34013498)
36. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003;77:875-82.
37. King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 1998;67:867-72. (Pubitemid 28196660)
38. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 2005;66:1256-60. (Pubitemid 41797301)
39. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003;63:2347-50. (Pubitemid 36605165)
40. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996;271:27456-61. (Pubitemid 26367305)
41. Calvo E, Malik SN, Siu LL, Baillargeon GM, Irish J, Chin SF, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 2007;18:761-7. (Pubitemid 46523282)
42. Gardner CD, Chatterjee LM, Franke AA. Effects of isoflavone supplements vs. soy foods on blood concentrations of genistein and daidzein in adults. J Nutr Biochem 2009;20:227-34.
43. Vergne S, Titier K, Bernard V, Asselineau J, Durand M, Lamothe V, et al. Bioavailability and urinary excretion of isoflavones in humans: effects of soy-based supplements formulation and equol production. J Pharm Biomed Anal 2007;43:1488-94.
44. Raju J, Swamy MV, Cooma I, Patlolla JM, Pittman B, Reddy BS, et al. Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence. Int J Cancer 2005;113:798-802. (Pubitemid 40101262)
45. Takimoto CH, Glover K, Huang X, Hayes SA, Gallot L, Quinn M, et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1213-21. (Pubitemid 37499447)
46. Sun CL, Yuan JM, Arakawa K, Low SH, Lee HP, Yu MC. Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 2002;11:1674-7. (Pubitemid 36020023)
47. Sun CL, Yuan JM, Wang XL, Gao YT, Ross RK, Yu MC. Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. Int J Cancer 2004;112:319-23. (Pubitemid 39244372)
48. Wu AH, Koh WP, Wang R, Lee HP, Yu MC. Soy intake and breast cancer risk in Singapore Chinese Health Study. Br J Cancer 2008;99:196-200. (Pubitemid 351920241)
49. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991;83:541-6.
50. Jian L. Soy, isoflavones, and prostate cancer. Mol Nutr Food Res 2009;53:217-26.
51. Messina M, Watanabe S, Setchell KD. Report on the 8th International Symposium on the role of soy in health promotion and chronic disease prevention and treatment. J Nutr 2009;139:796S-802S.
52. Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008;269:226-42.
53. Miodini P, Fioravanti L, DiFronzo G, Cappelletti V. The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. Br J Cancer 1999;80:1150-5. (Pubitemid 29264073)
54. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-6.
55. Sonpavde G, Okuno N, Weiss H, Yu J, Shen SS, Younes M, et al. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 2007;69:1221-6. (Pubitemid 46891583)